Provisional programme

Sunday 6 March 2011


18.00-19.00 Buffet dinner
19.00-20.50 Short position statements 
Chairs: Guy Goodwin, United Kingdom
Philippe Cupers, Belgium


19.00 Welcome and introduction 
Guy Goodwin, United Kingdom
19.05 The current and future size and burden of brain disorders in Europe
Hans-Ulrich Wittchen, Germany 
19.20 Health economics of brain disorders in Europe 
Bengt Jönsson, Sweden
19.35 The current position of the Pharmaceutical  Industry-1
Atul C. Pande, GSK
19.50 The current position of the Pharmaceutical Industry- 2
Anders G. Pedersen, Lundbeck
20.05 The current position of the Pharmaceutical Industry- 3
Jeffrey S. Nye, Johnson&Johnson
20.20 The current position of the European Union-1
20.35 The current position of the European Union-2
Philippe Cupers, EU DG Research, Innovation and Science

General discussion and scene-setting for tomorrow

21.30 Dessert and drinks


Monday 7 March 2011


08.30-10.30 The scientific dimension
Chairs: Patrice Boyer, France 
David Nutt, United Kingdom


08.30-08.35 Introduction
David Nutt, United Kingdom
08.35 Rationalising the approach to drug discovery for brain disorders
Sven Schellberg, Switzerland
08.50 Discussion  
09.00 Rationalising barriers to clinical research
Adam Cohen, The Netherlands     
09.15 Discussion 
09.25 Is there a role for academic networks?
Celso Arango, Spain  
09.40 Discussion
09.50 Sharing costs: Is the Innovative Medicines Initiative (IMI) a model for clinical
Shitij Kapur, United Kingdom


10.15 General discussion
10.30 Break


11.00-11.45 Regulatory challenges: past, present and future
Chairs: Christine Gispen-de Wied, EMA
David Nutt, United Kingdom


11.00 Introduction
Christine Gispen-de Wied, EMA   
11.05 EMA responsibilities and possibilities
Maria Isaac, EMA
11.20 Discussion 
11.30 Optimising guidelines 
Barbara van Zwieten-Boot, EMA   
11.45 Discussion 


11.55-12.25 The NIH approach to discovering new treatments
Chair: Joseph Zohar, Israel


11.55 Introduction
Joseph Zohar, Israel   
12.00 The NIH approach to discovering new treatments
Thomas R.  Insel, USA 
12.15 Discussion  
12.25 Lunch  


13.30-16.00 The future of CNS drug research in Europe
Chairs: Guy Goodwin, United Kingdom 
Thomas Lönngren, past-ED EMA
Facilitator: David Nutt, United Kingdom


13.30 General discussion and brainstorming of possible solutions 
15.30 Agreeing the ways forward and future meetings 
16.00 Closure of the meeting

Related pages / downloads